← Back to Screener
Climb Bio, Inc. Common Stock (CLYM)
Price$11.80
Momentum ScoreA
Favorite Metrics
Price vs S&P 500 (26W)517.60%
Price vs S&P 500 (4W)18.04%
VGM Score85.70
Market Capitalization$627.58M
All Metrics
Book Value / Share (Quarterly)$3.10
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.12
Price vs S&P 500 (YTD)163.07%
EPS (TTM)$-0.78
10-Day Avg Trading Volume0.68M
EPS Excl Extra (TTM)$-0.78
EPS (Annual)$-0.88
ROI (Annual)-37.30%
Cash / Share (Quarterly)$2.29
ROA (Last FY)-35.68%
EBITD / Share (TTM)$-0.88
ROE (5Y Avg)-33.67%
Cash Flow / Share (Annual)$-1.14
P/B Ratio4.24x
P/B Ratio (Quarterly)2.21x
Net Income / Employee (Annual)$-2,137,500
Net Interest Coverage (TTM)-29.57x
ROA (TTM)-30.39%
EPS Incl Extra (Annual)$-0.88
Current Ratio (Annual)15.16x
Quick Ratio (Quarterly)26.91x
3-Month Avg Trading Volume0.68M
52-Week Price Return798.36%
Revenue / Employee (TTM)$0
52-Week High$12.48
EPS Excl Extra (Annual)$-0.88
26-Week Price Return533.53%
Quick Ratio (Annual)14.47x
13-Week Price Return48.51%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)27.86x
Enterprise Value$619.22M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$2.12
3-Month Return Std Dev75.99%
Net Income / Employee (TTM)$-1,885,400
ROE (Last FY)-37.30%
Net Interest Coverage (Annual)-13.87x
EPS Basic Excl Extra (Annual)$-0.88
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.78
ROI (TTM)-31.46%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)770.15%
Year-to-Date Return174.00%
5-Day Price Return-0.36%
EPS Normalized (Annual)$-0.88
ROA (5Y Avg)-32.48%
Month-to-Date Return23.42%
EBITD / Share (Annual)$-1.00
ROI (5Y Avg)-33.67%
EPS Basic Excl Extra (TTM)$-0.78
P/B Ratio (Annual)1.70x
Book Value / Share (Annual)$3.36
Price vs S&P 500 (13W)38.76%
Beta0.13x
Revenue / Share (TTM)$0.00
ROE (TTM)-31.46%
52-Week Low$1.16
mGradeA
vgmGradeA
Show chart for
Earnings Surprise History
Q1 26-0.20est. -0.27
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.46
4.43
4.44
4.42
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CLYMClimb Bio, Inc. Common Stock | — | — | A | $11.80 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases. Its lead candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete B cells for the treatment of B-cell-mediated diseases.